1,721,000 research outputs found
Can We Predict The Clinical Outcomes Of Genitourinary Trauma Patients And Offer Them An Evidence-based Support? The Case For Telemedicine Network
No full text[No abstract available]32411071108von Klot, C.A.J., Zeckey, C., Tezval, H., Can we predict the clinical outcome of patients with bladder trauma? (2013) World J Urol, 31, pp. 1017-1018Pereira, B.M., de Campos, C.C., Calderan, T.R., Reis, L.O., Fraga, G.P., Bladder injuries after external trauma: 20 years experience report in a population-based cross-sectional view (2013) World J Urol, 31, pp. 913-917Reis, L.O., Kim, F.J., Moore, E.E., Hirano, E.S., Fraga, G.P., Nascimento, B., Rizoli, S., Update in the classification and treatment of complex renal injuries (2013) Rev Col Bras Cir, 40 (4), pp. 347-35
Variations Of Serum Testosterone Levels In Prostate Cancer Patients Under Lh-releasing Hormone Therapy: An Open Question
No full textThe hypothesis 'the lower the better when achieving castration levels of testosterone' is based on the data from second-line hormonal manipulation and its molecular basis, and on better oncological results reported for lower castration levels in prostate cancer (PCa) patients, including those achieved with maximal androgen blockade. In this regard, the equivalence of surgical and different pharmacological castrations has been controversial. The modified amino acid structure that makes LH-releasing hormone (LHRH) analogs more potent than LHRH, and the method of delivering the analogs impacts on bioavailibility and potentially causes differences in androgen levels and in its final oncological efficacy. In addition to this, there is a myriad of circumstances, such as those related to ethnic variations and co-morbidities, which uniquely impact on the pharmacological approach in a highly heterogeneous population of castration-resistant prostate cancer (CRPC) patients. Ineffective testosterone suppression through hormonal escape is currently poorly recognized and may result in increased PCa mortality. Until now, the optimal serum testosterone level in patients under castration, and the impact of its variations in patients under LHRH therapy, remain open questions and have been merged to a broad spectra of patients who are highly heterogeneous. This heterogeneity relates to a number of mechanisms regarding response to treatment, which influences the biology of the relapsing tumor and the sensitivity to subsequent therapies in the individual patient. The rationale to achieve testosterone levels below 20-50 ng/dl warrant further investigation as these levels have recently rescued CRPC patients. In the last few years and months, important advancements in prostate cancer treatment have been achieved. Nevertheless, these advances are measured in a few months of additional survival and under high costs, not available to most of the world population, compared with the benefits of hormonal manipulation that are measured in years, there is a huge potential for accessible and durable effect expansion and optimization of treatment, particularly with the current tendency of a more individual approach. © 2012 Society for Endocrinology.193R93R98Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J.B., Mirimanoff, R.O., Storme, G., Sternberg, C., Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial (2002) Lancet, 360, pp. 103-106. , doi:10.1016/ S0140-6736(02)09408-4Chodak, G.W., Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma (1989) Urology, 33, pp. 42-44. , doi:10.1016/0090- 4295(89)90105-2Fujii, Y., Yonese, J., Kawakami, S., Yamamoto, S., Okubo, Y., Fukui, I., Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer (2008) BJU International, 101, pp. 1096-1100. , doi:10.1111/j.1464-410X.2007.07374.xHeyns, C.F., Simonin, M.P., Grosgurin, P., Schall, R., Porchet, H.C., Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer (2003) BJU International, 92, pp. 226-231. , South African Triptorelin Study Group (doi:10.1046/j.1464-410X.2003. 04308.x)Hussain, M., Tangen, C.M., Higano, C., Schelhammer, P.F., Faulkner, J., Crawford, E.D., Wilding, G., Donnelly, B., Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162) (2006) Journal of Clinical Oncology, 24, pp. 3984-3990. , doi:10.1200/JCO.2006.06.4246Kaisary, A.V., Tyrrell, C.J., Peeling, W.B., Griffiths, K., Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma (1991) British Journal of Urology, 67, pp. 502-508. , doi:10.1111/ j.1464-410X.1991.tb15195.xLawrentschuk, N., Fernandes, K., Bell, D., Barkin, J., Fleshner, N., Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence (2011) Journal of Urology, 185, pp. 848-854. , doi:10.1016/j.juro.2010.10.055Marberger, M., Kaisary, A.V., Shore, N.D., Karlin, G.S., Savulsky, C., Mis, R., Leuratti, C., Germa, J.R., Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: A phase III, open-label, International Multicenter Study (2010) Clinical Therapeutics, 32, pp. 744-757. , doi:10.1016/ j.clinthera.2010.04.013Messing, E.M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E.D., Trump, D., Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer (1999) New England Journal of Medicine, 341, pp. 1781-1788. , doi:10.1056/NEJM199912093412401Morote, J., Orsola, A., Planas, J., Trilla, E., Raventós, C.X., Cecchini, L., Catalán, R., Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy (2007) Journal of Urology, 178, pp. 1290-1295. , doi:10.1016/j.juro.2007.05.129Morote, J., Planas, J., Salvador, C., Raventós, C.X., Catalán, R., Reventós, J., Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy (2009) BJU International, 103, p. 332. , doi:10.1111/j.1464-410X.2008.08062.xOefelein, M.G., Feng, A., Scolieri, M.J., Ricchiutti, D., Resnick, M.I., Reassessment of the definition of castrate levels of testosterone: Implications for clinical decision making (2000) Urology, 56, p. 1021. , doi:10.1016/S0090-4295(00)00793-7Perachino, M., Cavalli, V., Testosterone (T) level correlates with survival in pts with advanced prostate cancer (APC): The lower is really the better (2008) Journal of Urology, 179, p. 179. , doi:10.1016/S0022-5347(08)60520-0Perachino, M., Cavalli, V., Bravi, F., Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: Prognostic significance? (2010) BJU International, 105, p. 648. , doi:10.1111/j.1464-410X.2009.08814.xPilepich, M.V., Winter, K., Lawton, C.A., Krisch, R.E., Wolkov, H.B., Movsas, B., Hug, E.B., Grignon, D., Androgen suppression adjuvant to definitive radiotherapy in carcinomas of the prostate - Long term results of phase III RTOG85-31 (2005) International Journal of Radiation Oncology, Biology, Physics, 61, pp. 1285-1290. , doi:10.1016/j.ijrobp.2004. 08.047Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials (2000) Lancet, 355, p. 1491. , Prostate Cancer Trialists' Collaborative Group (doi:10.1016/S0140- 6736(00)02163-2)Reis, L.O., Old issues and new perspectives on prostate cancer hormonal therapy: The molecular substratum (2011) Medical Oncology, , in press. (doi:10.1007/s12032-011- 9991-z;PMID:21626233)Reis, L.O., Vieira, L.F., Zani, E.L., Denardi, F., De Oliveira, L.C., Ferreira, U., Assessment of serum chromogranin-A as prognostic factor in high-risk prostate cancer (2010) Journal of Investigative Medicine, 58, pp. 957-960. , doi:10.231/JIM. 0b013e3181f5d610Scher, H.I., Liebertz, C., Kelly, W.K., Mazumdar, M., Brett, C., Schwartz, L., Kolvenbag, G., Schwartz, M., Bicalutamide for advanced prostate cancer: The natural versus treated history of disease (1997) Journal of Clinical Oncology, 15 (8), pp. 2928-2938Schmitt, B., Bennett, C., Seidenfeld, J., Samson, D., Wilt, T., Maximal androgen blockade for advanced prostate cancer (2000) Cochrane Database of Systematic Reviews, 2. , CD001526. (doi:10.1002/14651858.CD001526)Scholz, M., Lam, R., Strum, S., Jennrich, R., Johnson, H., Trilling, T., Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone- inactivating pharmaceuticals (2007) Urology, 70, pp. 506-510. , doi:10.1016/ j.urology.2007.04.015Seidenfeld, J., Samson, D.J., Hasselblad, V., Aronson, N., Albertsen, P.C., Bennett, C.L., Wilt, T.J., Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis (2000) Annals of Internal Medicine, 132 (7), pp. 566-577Sharifi, R., Bruskewitz, R.C., Gittleman, M.C., Graham Jr., S.D., Hudson, P.B., Stein, B., Leuprorelin acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer (1996) Clinical Therapeutics, 18, p. 647. , doi:10.1016/S0149-2918(96)80215-3Silva, E.D., Ferreira, U., Matheus, W., Faria, E.F., Silva, G.D., Saito, M., Goserelin versus leuprolide in the chemical castration of patients with prostate cancer (2012) International Urology and Nephrology, , [in press]. doi:10.1007/s11255- 012-0134-z;PMID:22315155Smith, M.R., Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer (2007) Clinical Cancer Research, 13, p. 241. , doi:10.1158/1078-0432. CCR-06-2086Smith, M., McGovern, F., Gonadotropin releasing hormone agonist failure in a man with prostate cancer (2001) Journal of Urology, 166, p. 211. , doi:10.1016/S0022- 5347(05)66115-0Suzuki, H., Okihara, K., Miyake, H., Fujisawa, M., Miyoshi, S., Matsumoto, T., Fujii, M., Matsuda, T., Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade (2008) Journal of Urology, 180, pp. 921-927. , doi:10.1016/j.juro.2008.05.045Tanaka, N., Fujimoto, K., Hirao, Y., Shimizu, K., Tsujimoto, S., Samma, S., Endocrine response to a single injection of goserelin 3.6 mg or leuprolide 3.75 mg in men with prostate cancer (2007) Archives of Andrology, 53, p. 289. , doi:10.1080/01485010701601222Tombal, B., Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: What is the optimal level of testosterone (2005) European Urology Supplements, 4 (5), pp. 14-19. , doi:10.1016/j.eursup.2005.04.004Vogelzang, N.J., Chodak, G.W., Soloway, M.S., Block, N.L., Schellhammer, P.F., Smith Jr., J.A., Caplan, R.J., Kennealey, G.T., Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomized trial (1995) Urology, 46, pp. 220-226. , Zoladex Prostate Study Group. doi:10.1016/S0090-4295(99)80197-6Wheeler, M.J., D'Souza, A., Matadeen, J., Croos, P., Ciba Corning ACS: 180 Testosterone assay evaluated (1996) Clinical Chemistry, 42, p. 1445Wilke, T.J., Utley, D.J., Total testosterone, free-androgen index, calculated free testosterone, and free testosterone by analog RIA compared in hirsute women and otherwise normal women with altered binding of sex-hormone binding globulin (1987) Clinical Chemistry, 33, p. 1372Yri, O.E., Bjoro, T., Fossa, S.D., Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer (2006) European Urology, 49, p. 54. , doi:10.1016/j.eururo.2005.09.009Zherdev, A.V., Byzova, N.A., Izumrudov, V.A., Dzantiev, B.B., Rapid polyelectrolyte-based immunofiltration technique for testosterone detection in serum samples (2003) Analyst, 128, p. 1275. , doi:10.1039/b303288
Going Beyond Counting First Authors in Author Co-citation Analysis
Get PDFThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Get PDF“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Get PDFWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Dispelling the Myths Behind First-author Citation Counts
Get PDFWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
koamabayili/VECTRON-author-checklist: VECTRON author checklist
No full textWe have done our best to complete the author checklist relating to the use of animals in the hut study. Note that the objective for the hut study was to evaluate the IRS treatment applications for residual efficacy against Anopheles mosquitoes, including the local An. coluzzii mosquito population. Cows were only used to attract mosquitoes into the huts and no tests were carried out directly on the cows. The author checklist is intended for use with studies where experiments are carried out on animals, which is why we have had such difficulty in completing this for the hut study, as many of the questions do not relate to how the cows were used
Author-wise bibliometric analysis based on entropy.
No full textAuthor-wise bibliometric analysis based on entropy.</p
- …
